Access cutting-edge beta-thalassemia treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access beta-thalassemia specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related beta-thalassemia treatment provided free
This is a Phase 2a study to evaluate the safety and pharmacokinetics (PK) of luspatercept in pediatric participants with β-thalassemia. The study will be conducted in 2 parts for both transfusion-dependent (TD) and non-transfusion-dependent (NTD) β-thalassemia participants: TD Part A will be in adolescent participants aged 12 to \<18 years with two dose escalation cohorts, followed by a dose expansion cohorts. NTD Part A will be conducted in the same age group participants as TD Part A with dos
Sponsor: Celgene
Check if you qualify for this beta-thalassemia clinical trial in New York, NY
If you're searching for beta-thalassemia treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced beta-thalassemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.